文献速递核素与放射性配体治疗放射性药物与辐射防护

177Lu-PSMA放射性配体治疗的长期肾毒性

Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy.
PubMed 文献 · J Nucl Med · 2024-01-02

该回顾性研究纳入3家德国三级转诊中心106例接受至少4个周期177Lu-PSMA且随访至少12个月的转移性去势抵抗性前列腺癌患者,发现45%(48/106)出现至少中度eGFR下降,其中近半(23/48)为重度或极重度下降;基线风险因素越多与eGFR下降越大相关。

要点

  • 45%(48/106)患者出现至少中度eGFR下降,其中23/48为重度或极重度下降。
  • 基线风险因素数量较多与eGFR下降幅度更大相关(-4.51,P=0.03)。
  • 作者认为相当比例患者可能在177Lu-PSMA开始后1年出现中度或重度eGFR下降。

核心结论

  • 相当比例的患者可能在177Lu-PSMA开始后1年出现中度或重度eGFR下降。
  • 基线风险因素数量较多似乎会加重肾功能丧失。
  • 需要进一步前瞻性试验来评估177Lu-PSMA的肾毒性潜力。

研究设计与样本

  • 回顾性评估转移性去势抵抗性前列腺癌患者接受177Lu-PSMA后至少12个月的eGFR动态变化。
  • 3家德国三级转诊中心的机构数据库识别出106例接受至少4个周期177Lu-PSMA且具有至少12个月eGFR随访数据的患者。
  • 采用单指数拟合曲线估算177Lu-PSMA放射性配体治疗后3、6、12个月的eGFR(按慢性肾脏病流行病学协作组公式)。
  • eGFR变化分组:≥15%-<30%为中度,≥30%-<40%为重度,≥40%为极重度。
  • 采用多变量线性回归分析eGFR变化(%)与肾毒性风险因素、既往治疗线数及177Lu-PSMA周期数的关联。

主要发现

  • 45%(48/106)患者出现至少中度eGFR下降。
  • 在48例至少中度eGFR下降患者中,近半(23/48)为重度或极重度eGFR下降。
  • 基线风险因素数量较多与eGFR下降幅度更大相关(-4.51,P=0.03)。

关键数值与推荐

  • eGFR变化分组标准:≥15%-<30%为中度,≥30%-<40%为重度,≥40%为极重度。
  • 至少中度eGFR下降者占45%(48/106)。
  • 基线风险因素数量与eGFR变化的回归系数为-4.51(P=0.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 回顾性设计。
  • 缺乏对照组。
  • 随访超过1年的患者数量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

β-emitting 177Lu targeting prostate-specific membrane antigen (PSMA) is an approved treatment option for metastatic castration-resistant prostate cancer. Data on its long-term nephrotoxicity are sparse. This study aimed to retrospectively evaluate post-177Lu-PSMA estimated glomerular filtration rate (eGFR) dynamics for at least 12 mo in a cohort of metastatic castration-resistant prostate cancer patients. Methods: The institutional databases of 3 German tertiary referral centers identified 106 patients who underwent at least 4 cycles of 177Lu-PSMA and had at least 12 mo of eGFR follow-up data. eGFR (by the Chronic Kidney Disease Epidemiology Collaboration formula) at 3, 6, and 12 mo after 177Lu-PSMA radioligand therapy was estimated using monoexponentially fitted curves through available eGFR data. eGFR changes were grouped (≥15%-<30%, moderate; ≥30%-<40%, severe; and ≥40%, very severe). Associations between eGFR changes (%) and nephrotoxic risk factors, prior treatment lines, and number of 177Lu-PSMA cycles were analyzed using multivariable linear regression. Results: At least moderate eGFR decreases were present in 45% (48/106) of patients; of those, nearly half (23/48) had a severe or very severe eGFR decrease. A higher number of risk factors at baseline (-4.51, P = 0.03) was associated with a greater eGFR decrease. Limitations of the study were the retrospective design, lack of a control group, and limited number of patients with a follow-up longer than 1 y. Conclusion: A considerable proportion of patients may experience moderate or severe decreases in eGFR 1 y from initiation of 177Lu-PSMA. A higher number of risk factors at baseline seems to aggravate loss of renal function. Further prospective trials are warranted to estimate the nephrotoxic potential of 177Lu-PSMA.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Steinhelfer L, Lunger L, Cala L, et al. Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy. J Nucl Med. 2024. PMID: 37857504. doi:10.2967/jnumed.123.265986

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。